Oct. 12 (Wed.) ,2016 15:00-17:00

Annex Hall

Simultaneous Interpretation

Commercialization and R&D of RM Products:
Japanese Current Circumstances

With the new system enforcement of regenerative medicine, an environment promoting industrialization is put into place and the number of companies seriously entering the regenerative medicine is increasing. Taking this opportunity, we would like to discuss the present and future of the regenerative medicine industry to the companies promoting the business; companies that recently entered the market; and those who will soon enter the market, to shed light to the challenges of regenerative medicine industrialization. Moreover, we will introduce the latest research on the measures of the immune rejection of allogeneic cells, which is an issue of regenerative medicine industrialization.


Yasuhiro Yoshioka


J-TEC's Business Overview

Aiichiro Hiruma

President & CEO, Japan Tissue Engineering

Development of HeartSheet®

Tadashi Sameshima

Executive Officer, HeartSheetBusiness Dept., Terumo

Development and Approval of Allogeneic Stem Cell Product “TEMCELL® HS inj”

Zen-ichi Mohri

Advisor for Development, JCR Pharmaceuticals

Development of Regenerative Medical Products from iPSC; Current Issue and Future Direction

Toru Kimura

Member, Board of Directors, Executive Officer Regenerative & Cellular Medicine Senior Director, Global Corporate Planning;, Sumitomo Dainippon Pharma Co.,Ltd.

A Novel Drug Development for Transplant Tolerance

Yasuyuki Ishii

Executive Chairman, REGiMMUNE

Close Window